The DEA will set new rules for the development of medical cannabis research

The U.S. federal agency is currently proposing a new set of rules that would allow the development of scientific research on medical cannabis in the United States. These rules will follow international regulations and will give the power to The Drug Enforcement Administration (DEA) to be the sole importer of cannabis and cannabis resin for research in the North American country.

The Drug Enforcement Administration (DEA), the U.S. federal agency responsible for combating drug trafficking and distribution in the United States of America, proposed new rules that would expand the opportunities for scientific and medical research on cannabis.

DEA had initially announced that it would increase the number of legal cannabis growers back in 2016, prompting 37 different entities to submit applications for registration with the agency. However, the federal agency did not respond to any of these applications. DEA announced in 2019 that it will create new rules before new federally registered growers could be registered.

Currently, only one institution in all the United States, located at the University of Mississippi, is licensed to produce cannabis for research purposes.

If you want to know more about the future plans of the Drug Enforcement Administration (DEA) in the United States, how the U.S. federal agency will regulate cannabis in the country and to find out the latest hemp news, download the Hemp.im mobile application to your smartphone or tablet.

The Drug Enforcement Administration to manage the distribution of cannabis grown for research.

“The Drug Enforcement Administration (DEA) continues to support additional research on cannabis and its components, and we believe that the registration of more growers will further advance the scientific and medical research already underway,” said Uttam Dhillon, Acting Administrator of The Drug Enforcement Administration (DEA).

“The Drug Enforcement Administration (DEA) wants to register additional cannabis growers for federally-authorized research and will continue to work with other appropriate federal agencies to expedite the next steps,” he continued.

Under the proposed rules, the The Drug Enforcement Administration (DEA) would manage the distribution of cannabis grown for research. Growers would be required to sell their product to the agency, which would then sell it to researchers for approved studies. Currently, the agency’s only cannabis grower supplies cannabis for research directly to researchers, without The Drug Enforcement Administration (DEA) acting as an intermediary.

The U.S. federal agency will follow all the United Nations treaties

The Drug Enforcement Administration (DEA) explained that it would thus comply with the United Nations treaties governing research on controlled substances. The agency stated that international regulations also require that the United States federal agency be the sole importer of cannabis and cannabis resin for research in the country, although the requirement does not apply to approved medical cannabis preparations.

The note from The Drug Enforcement Administration (DEA) and the Department of Justice also explained that since 2017, the number of institutions authorized to conduct cannabis research has increased by 58%. The agency also increased the quota of cannabis produced for research from 472 kilograms in 2017 to 3,200 kilograms in 2020.

The announced rule change will now go through a 60-day public comment period on the proposal. The Drug Enforcement Administration (DEA) stated that the proposed rule change is “the latest and most important step taken to increase the number of registered cannabis growers in the United States, and underscores the federal government’s support for scientific and medical research on cannabis and its chemical components.

__

(Featured image by Louis Velazquez on Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Newsfeed.fr, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.